INT18393

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 15
Total Number 15
Disease Relevance 3.63
Pain Relevance 7.57

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Ryr1) plasma membrane (Ryr1) cytoplasm (Ryr1)
Ryr1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 37 100.00 Very High Very High Very High
cytokine 22 100.00 Very High Very High Very High
Dopamine 9 100.00 Very High Very High Very High
Clonidine 44 99.98 Very High Very High Very High
agonist 11 99.78 Very High Very High Very High
antagonist 22 99.46 Very High Very High Very High
Eae 4 99.32 Very High Very High Very High
Morphine 11 98.52 Very High Very High Very High
dopamine receptor 1 98.28 Very High Very High Very High
opiate 5 95.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 50 100.00 Very High Very High Very High
Disease 14 99.56 Very High Very High Very High
Pancreatitis 16 98.48 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 4 97.84 Very High Very High Very High
Tremor 3 95.04 Very High Very High Very High
Heart Rate Under Development 2 93.24 High High
Poisoning 20 89.60 High High
Pain 16 86.28 High High
Targeted Disruption 8 84.32 Quite High
Toxicity 5 82.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have previously shown that RYR inhibition reduces pathological intra-acinar protease activation, an early marker of pancreatitis.
Negative_regulation (inhibition) of RYR associated with pancreatitis
1) Confidence 0.43 Published 2010 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 20448143 Disease Relevance 0.48 Pain Relevance 0.13
Blockade of Ca(2+) signals and particularly RYR-Ca(2+) may be useful as prophylactic treatment for this disease in high-risk settings for pancreatitis.
Negative_regulation (Blockade) of RYR associated with pancreatitis and disease
2) Confidence 0.37 Published 2010 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 20448143 Disease Relevance 0.77 Pain Relevance 0
These inhibitory effects are presumably due to the inhibition of Ca-release from storage sites and to the block of Ca-influx.
Negative_regulation (inhibition) of Ca-release
3) Confidence 0.29 Published 1984 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 6482091 Disease Relevance 0 Pain Relevance 0.09
The effects of CGS 10746B, a dopamine release inhibitor, on spontaneous locomotor activity, morphine-induced hyperactivity, acquisition of conditioned place paradigm and morphine-induced conditioned place preference (CPP) was evaluated in male mice.
Negative_regulation (inhibitor) of release associated with dopamine, eae, attention deficit hyperactivity disorder and morphine
4) Confidence 0.18 Published 2001 Journal Behav. Brain Res. Section Abstract Doc Link 11704248 Disease Relevance 0.17 Pain Relevance 0.64
The anesthetic-induced [3H]5-HT release depends on the ryanodine-sensitive intracellular calcium store since it was blocked by dantrolene and azumolene (inhibitors of the calcium-release through ryanodine receptors) but was not affected by aminoethoxydiphenylborate (2-APB), an inhibitor of inositol 1,4,5-triphosphate receptor.
Negative_regulation (inhibitors) of calcium-release
5) Confidence 0.08 Published 2008 Journal Neurochem. Int. Section Abstract Doc Link 18282641 Disease Relevance 0 Pain Relevance 0.70
The protective effects of clonidine are probably due to blockade of acetylcholine release and postmuscarinic receptors, together with transient inhibition of acetylcholinesterase.
Negative_regulation (blockade) of acetylcholine release associated with clonidine
6) Confidence 0.04 Published 2002 Journal Crit Care Section Body Doc Link PMC137451 Disease Relevance 0.53 Pain Relevance 0.35
It also inhibits acetylcholine release [4].
Negative_regulation (inhibits) of acetylcholine release
7) Confidence 0.03 Published 2002 Journal Crit Care Section Body Doc Link PMC137451 Disease Relevance 0.63 Pain Relevance 0.29
The protective effects of clonidine are likely to involve multiple effects, including blockade of acetylcholine release and postsynaptic muscarinic receptors and transient inhibition of acetylcholinesterase.
Negative_regulation (blockade) of acetylcholine release associated with clonidine
8) Confidence 0.02 Published 1986 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3761196 Disease Relevance 0.29 Pain Relevance 0.57
Interestingly, some studies have also demonstrated that release of the ‘anti-inflammatory–cytokine, IL-10, is impaired in P2X7????
Negative_regulation (impaired) of release associated with inflammation and cytokine
9) Confidence 0.01 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2096758 Disease Relevance 0.77 Pain Relevance 0.56
Alpha-2 adrenergic inhibition of Ca(++)-evoked [3H]norepinephrine release from synaptosomes is blocked by depolarization.
Negative_regulation (inhibition) of release
10) Confidence 0.00 Published 1990 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 1972747 Disease Relevance 0 Pain Relevance 0.58
The alpha-2 adrenergic antagonists idazoxan and yohimbine reversed clonidine inhibition of release whereas the alpha-1 antagonist prazosin did not.
Negative_regulation (inhibition) of release associated with antagonist and clonidine
11) Confidence 0.00 Published 1990 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1972747 Disease Relevance 0 Pain Relevance 0.68
However, at [K+] above 9 mM, inhibition of Ca(++)-evoked release by clonidine decreased, and by 20 mM [K+] clonidine no longer inhibited release.
Negative_regulation (inhibition) of release associated with clonidine
12) Confidence 0.00 Published 1990 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1972747 Disease Relevance 0 Pain Relevance 0.78
However, at [K+] above 9 mM, inhibition of Ca(++)-evoked release by clonidine decreased, and by 20 mM [K+] clonidine no longer inhibited release.
Negative_regulation (inhibited) of release associated with clonidine
13) Confidence 0.00 Published 1990 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1972747 Disease Relevance 0 Pain Relevance 0.79
The alpha-2 adrenergic agonist clonidine inhibited 60% of the Ca(++)-evoked [3H]norepinephrine release.
Negative_regulation (inhibited) of release associated with agonist and clonidine
14) Confidence 0.00 Published 1990 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1972747 Disease Relevance 0 Pain Relevance 0.60
The effects of the D2-dopamine receptor selective agonist LY 171555 and the D2-receptor antagonist domperidone on the evoked DA-release were reduced by 1 microM urapidil.
Negative_regulation (reduced) of DA-release associated with dopamine, antagonist, dopamine receptor and agonist
15) Confidence 0.00 Published 1987 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 2883943 Disease Relevance 0 Pain Relevance 0.79

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox